Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Pfizer Enters $226 Million China/Asia Deal for Basilea's Anti-Fungal Drug

publication date: Dec 4, 2017

Pfizer signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug developed by Swiss pharma Basilea. Previously, Pfizer acquired rights for Cresemba in Europe, Russia, Turkey and Israel. In the latest deal, Pfizer in-licensed rights for China (including Hong Kong and Macao) and sixteen countries in the Asia Pacific region. Isavuconazole is an antifungal aimed at life-threatening invasive mold infections. Pfizer will develop, manufacture and commercialize isavuconazole in China and the Asia Pacific region. More details....

Stock Symbols: (NYSE: PFE) (SIX: BSLN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China